CAPOS syndrome
CAPOS syndrome is a rare genetic disorder characterized by Cerebellar ataxia, Areflexia, Pes cavus, Optic atrophy, and Sensorineural hearing loss. The syndrome was first described in 1996 by Nicolaides and Appleton. The name CAPOS is an acronym derived from the initial letters of these five main features.
Clinical Features
Cerebellar ataxia is a form of ataxia originating in the cerebellum. It results in unsteady movements and a lack of coordination.
Areflexia is a condition in which the muscles do not respond to stimuli as they should. This can lead to difficulties with movement and coordination.
Pes cavus is a high arch of the foot that does not flatten with weight bearing. This can lead to instability and a variety of foot problems.
Optic atrophy refers to the degeneration of the optic nerve, which can lead to vision loss.
Sensorineural hearing loss is a type of hearing loss in which the root cause lies in the inner ear or sensory organ (cochlea and associated structures) or the vestibulocochlear nerve (cranial nerve VIII).
Genetics
CAPOS syndrome is caused by mutations in the ATP1A3 gene. This gene provides instructions for making a protein that is found in nerve cells, where it helps maintain the proper balance of charged atoms (ions) inside these cells. Mutations in the ATP1A3 gene alter the function of this protein, which disrupts ion balance in nerve cells and leads to the features of CAPOS syndrome.
Diagnosis and Treatment
Diagnosis of CAPOS syndrome is based on the presence of the characteristic clinical features. Genetic testing can confirm the diagnosis. Treatment is symptomatic and supportive, focusing on managing each of the individual symptoms.
See Also
- Genetic disorder
- Cerebellar ataxia
- Areflexia
- Pes cavus
- Optic atrophy
- Sensorineural hearing loss
- ATP1A3
| Genetic disorders | ||||||||
|---|---|---|---|---|---|---|---|---|
This genetic disorder related article is a stub.
|
NIH genetic and rare disease info
CAPOS syndrome is a rare disease.
| Rare and genetic diseases | ||||||
|---|---|---|---|---|---|---|
|
Rare diseases - CAPOS syndrome
|
Ad. Transform your health with W8MD Weight Loss, Sleep & MedSpa

Tired of being overweight?
Get started with evidence based, physician-supervised
affordable GLP-1 weight loss injections
Now available in New York City and Philadelphia:
- Semaglutide starting from $59.99/week and up
- Tirzepatide starting from $69.99/week and up (dose dependent)
✔ Evidence-based medical weight loss ✔ Insurance-friendly visits available ✔ Same-week appointments, evenings & weekends
Learn more:
Start your transformation today with W8MD weight loss centers.
|
WikiMD Medical Encyclopedia |
Medical Disclaimer: WikiMD is for informational purposes only and is not a substitute for professional medical advice. Content may be inaccurate or outdated and should not be used for diagnosis or treatment. Always consult your healthcare provider for medical decisions. Verify information with trusted sources such as CDC.gov and NIH.gov. By using this site, you agree that WikiMD is not liable for any outcomes related to its content. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian


